Cell Growth & Differentiation, Vol 7, Issue 3 351-359, Copyright © 1996 by American Association of Cancer Research

ARTICLES

Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity

JA Dumont, AJ Bitonti, CD Wallace, RJ Baumann, EA Cashman and DE Cross-Doersen
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215, USA.

We have isolated a variant of the MCF-7 human breast tumor that is characterized by a hormone-independent, yet hormone-responsive, phenotype. This tumor, designated MCF-WES, was derived from MCF-7 tumor cells implanted in the mammary fat pad of a nude mouse in the absence of estradiol supplementation. MCF-WES tumors remain responsive to estradiol; however, unlike the parental MCF-7 tumors, they are stimulated to grow by tamoxifen. Additionally, MCF-WES cells are resistant to the pure steroidal antiestrogen, ICI 182,780. To our knowledge, a tumor with this combination of properties has not yet been described. Nuclear estrogen receptor (ER) levels in MCF-WES cells were 10% of those for MCF-7 under steroid-depleted conditions. MCF-WES tumor ER levels were 32% of those in MCF-7 tumors. Similarly, in vivo expression of ER mRNA for MCF-WES was 20% of levels determined for MCF-7. Further characterization of MCF-WES cells showed that they have increased levels of AP-1 DNA-binding activity. The marked increase in AP-1 binding activity may act to bypass the hormone dependence that is a characteristic of MCF-7 cells. It is also probable that the increase in AP-1 binding activity is responsible for the finding that MCF-WES cells secrete greater quantities of metalloproteinase activity in comparison to parental MCF-7 cells, suggesting progression to a more invasive, malignant phenotype. More complete characterization of this new cell line will help elucidate hormone-independent breast cancer and possibly identify targets for therapy.

This article has been cited by other articles:

				X. Lin, Y. Yu, H. Zhao, Y. Zhang, J. Manela, and D. A. Tonetti Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model Carcinogenesis, August 1, 2006; 27(8): 1538 - 1546. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				J. N. Holloway, S. Murthy, and D. El-Ashry A Cytoplasmic Substrate of Mitogen-Activated Protein Kinase Is Responsible for Estrogen Receptor-{alpha} Down-Regulation in Breast Cancer Cells: The Role of Nuclear Factor-{kappa}B Mol. Endocrinol., June 1, 2004; 18(6): 1396 - 1410. [Abstract] [Full Text] [PDF]

				D.-X. Hou, K. Kai, J.-J. Li, S. Lin, N. Terahara, M. Wakamatsu, M. Fujii, M. R. Young, and N. Colburn Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms Carcinogenesis, January 1, 2004; 25(1): 29 - 36. [Abstract] [Full Text] [PDF]

				H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al. Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597. [Abstract] [Full Text] [PDF]

				M. Fan, R. M. Bigsby, and K. P. Nephew The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-{alpha} and Essential for the Antiproliferative Activity of ICI 182,780 in ER{alpha}-Positive Breast Cancer Cells Mol. Endocrinol., March 1, 2003; 17(3): 356 - 365. [Abstract] [Full Text] [PDF]

				Q.-B. She, N. Chen, A. M. Bode, R. A. Flavell, and Z. Dong Deficiency of c-Jun-NH2-terminal Kinase-1 in Mice Enhances Skin Tumor Development by 12-O-Tetradecanoylphorbol-13-Acetate Cancer Res., March 1, 2002; 62(5): 1343 - 1348. [Abstract] [Full Text] [PDF]

				M. J. Chisamore, Y. Ahmed, D. J. Bentrem, V. C. Jordan, and D. A. Tonetti Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C{alpha} Clin. Cancer Res., October 1, 2001; 7(10): 3156 - 3165. [Abstract] [Full Text] [PDF]

				R. A. McClelland, D. Barrow, T.-A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. W. Gee, and R. I. Nicholson Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex) Endocrinology, July 1, 2001; 142(7): 2776 - 2788. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				R. Schiff, P. Reddy, M. Ahotupa, E. Coronado-Heinsohn, M. Grim, S. G. Hilsenbeck, R. Lawrence, S. Deneke, R. Herrera, G. C. Chamness, et al. Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo J Natl Cancer Inst, December 6, 2000; 92(23): 1926 - 1934. [Abstract] [Full Text] [PDF]

				L. Adam, R. Vadlamudi, M. Mandal, J. Chernoff, and R. Kumar Regulation of Microfilament Reorganization and Invasiveness of Breast Cancer Cells by Kinase Dead p21-activated Kinase-1 J. Biol. Chem., April 14, 2000; 275(16): 12041 - 12050. [Abstract] [Full Text] [PDF]

				A. H. Talukder, L. Adam, A. Raz, and R. Kumar Heregulin Regulation of Autocrine Motility Factor Expression in Human Tumor Cells Cancer Res., January 1, 2000; 60(2): 474 - 480. [Abstract] [Full Text]

				J. Y. Chung, C. Huang, X. Meng, Z. Dong, and C. S. Yang Inhibition of Activator Protein 1 Activity and Cell Growth by Purified Green Tea and Black Tea Polyphenols in H-ras-transformed Cells: Structure-Activity Relationship and Mechanisms Involved Cancer Res., September 1, 1999; 59(18): 4610 - 4617. [Abstract] [Full Text] [PDF]

				S. R. D. Johnston, B. Lu, G. K. Scott, P. J. Kushner, I. E. Smith, M. Dowsett, and C. C. Benz Increased Activator Protein-1 DNA Binding and c-Jun NH2-Terminal Kinase Activity in Human Breast Tumors with Acquired Tamoxifen Resistance Clin. Cancer Res., February 1, 1999; 5(2): 251 - 256. [Abstract] [Full Text] [PDF]

				A. Philips, C. Teyssier, F. Galtier, C. Rivier-Covas, J.-M. Rey, H. Rochefort, and D. Chalbos FRA-1 Expression Level Modulates Regulation of Activator Protein-1 Activity by Estradiol in Breast Cancer Cells Mol. Endocrinol., July 1, 1998; 12(7): 973 - 985. [Abstract] [Full Text]

				P. Bhat-Nakshatri, T. R. Newton, R. Goulet Jr., and H. Nakshatri NF-kappa B activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha PNAS, June 9, 1998; 95(12): 6971 - 6976. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]